Octreotide Acetate

Introduction Overview

Generic Name

octreotide acetate

Brand Name

Sandostatin, Mycapssa, Bynfezia Pen

Dosage Form

Injection, solution (subcutaneous, intravenous)

Drug Class

Somatostatin and somatostatin analogs

Pharmacokinetics

Absorption:
Octreotide acetate is rapidly and completely absorbed after subcutaneous injection, with peak plasma concentrations (e.g., 5.2 ng/mL for 100 mcg dose) achieved approximately 0.4 to 0.7 hours post-dose. The bioavailability of subcutaneous injection is equivalent to intravenous administration. Pharmacokinetic parameters such as peak concentrations and area under the curve (AUC) demonstrate dose proportionality across doses up to 500 mcg administered subcutaneously or 200 mcg intravenously, including multiple daily dosing.

Distribution:
Once absorbed, octreotide quickly distributes from plasma, with a distribution half-life around 0.2 hours. The volume of distribution at steady state (Vdss) ranges from approximately 13.6 L in healthy adults to 21.6 ± 8.5 L in acromegalic patients, likely reflecting disease-specific alterations. Plasma protein binding is about 65% in healthy subjects but reduced to approximately 41% in patients with acromegaly; binding occurs mainly to lipoproteins and, to a lesser extent, albumin. Octreotide's erythrocyte uptake is minimal.

Metabolism:
Octreotide is a synthetic octapeptide analog of somatostatin and undergoes limited metabolic transformation. Its molecular configuration confers resistance to rapid enzymatic breakdown compared to endogenous somatostatin, resulting in prolonged plasma half-life (1.7 to 1.9 hours vs. 1–3 minutes). Metabolic pathways are presumed to involve peptidases but detailed hepatic metabolism via cytochrome P450 enzymes is minimal. The suppression of growth hormone may modulate hepatic cytochrome P450 enzyme activity, potentially affecting metabolism of coadministered drugs.

Elimination:
Approximately 32% of octreotide is excreted unchanged by renal clearance. The elimination half-life ranges from 1.7 to 1.9 hours in healthy individuals, with longer half-lives observed in elderly patients (increased by ~46%) and those with hepatic or renal impairment. In renal insufficiency, clearance decreases significantly, requiring dose adjustments, while hepatic cirrhosis prolongs half-life and reduces clearance. Overall, total body clearance varies between 7 and 18 L/hr depending on patient condition, and dose modifications may be necessary based on renal or hepatic function. Patients on dialysis display a reduced clearance (~50%).

Dosage Forms

Available Dosage Forms:
Octreotide Acetate Injection is supplied as a sterile solution for parenteral administration in both single-dose and multi-dose vials. Single-dose vials contain 1 mL solutions at strengths of 50 mcg/mL, 100 mcg/mL, and 500 mcg/mL. Multi-dose vials are available in 5 mL volumes containing 200 mcg/mL (1,000 mcg/5 mL) and 1,000 mcg/mL (5,000 mcg/5 mL) octreotide acetate.

Dosages for Adults and Adolescents:
For acromegaly, initial subcutaneous dosing starts at 50 mcg three times daily, titrated based on growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels, with maintenance doses ranging from 100 to 500 mcg three times daily. For carcinoid tumors, dosing typically ranges from 100 to 600 mcg daily, divided into two to four subcutaneous injections, with an average maintenance dose of approximately 450 mcg/day; doses up to 1,500 mcg/day have been used in clinical practice though with limited experience above 750 mcg/day. For vasoactive intestinal peptide tumors (VIPomas), doses of 200 to 300 mcg per day, divided into multiple injections, are standard, with individual doses between 150 to 750 mcg/day to control symptoms.

Specific Patient Populations:
In patients with renal impairment, particularly those on dialysis, clearance is reduced approximately by half, requiring dose adjustments. Hepatic impairment, particularly liver cirrhosis, prolongs elimination half-life and reduces clearance, necessitating careful dose titration. Pediatric use is not well established; safety and efficacy have not been demonstrated in children under six, with higher risks of serious adverse events noted in young children under two years. Geriatric patients may exhibit altered pharmacokinetics warranting cautious dose initiation. The injectable solution is intended for subcutaneous or intravenous administration; sites should be rotated to minimize injection site complications.

Mechanism Of Action

Octreotide acetate is a synthetic cyclic octapeptide designed to mimic the effects of natural somatostatin but with a prolonged half-life and greater potency. It primarily exerts its pharmacologic action by binding to somatostatin receptors 2 and 5, which are G protein-coupled receptors widely expressed in the pituitary gland, pancreas, gastrointestinal tract, and various neuroendocrine tumors. Engagement of these receptors inhibits the secretion of multiple key hormones, including growth hormone (GH), insulin, glucagon, vasoactive intestinal peptide (VIP), gastrin, serotonin, secretin, motilin, pancreatic polypeptide, and luteinizing hormone (LH).

On a cellular level, receptor activation by octreotide leads to inhibition of adenylate cyclase activity, reduction in intracellular cyclic AMP (cAMP) levels, and modulation of ion channels, causing decreased hormone exocytosis. In the pituitary, inhibition of GH release leads to reduced peripheral production of insulin-like growth factor 1 (IGF-1), which mediates many of the growth-promoting effects seen in acromegaly. In neuroendocrine tumors such as carcinoid tumors and VIPomas, octreotide suppresses hormone secretion responsible for clinical symptoms like flushing and diarrhea.

Biochemically, octreotide decreases splanchnic blood flow, which helps mitigate symptoms related to hormone excess and tumor vascularity. It also inhibits gallbladder contractility and decreases bile secretion, contributing to gallstone formation in some patients. The inhibitory effects on hormone secretion and splanchnic circulation make octreotide valuable in managing hormone-related symptoms and complications in various tumors.

Comparatively, octreotide's mechanism resembles endogenous somatostatin but with improved pharmacokinetics and receptor affinity, providing longer duration and greater effectiveness than the natural hormone. Clinical studies have demonstrated that octreotide effectively suppresses GH and IGF-1 levels in acromegaly, controls flushing and diarrhea in carcinoid syndrome, and reduces VIP-mediated symptoms, validating its mechanism. Ongoing research explores its receptor interactions and potential applications in other hormonal and gastrointestinal disorders.

Pharmacological Actions

Potent inhibition of growth hormone (GH) secretion, leading to reduction of IGF-1 levels.
Suppression of insulin and glucagon secretion, affecting glucose homeostasis and requiring monitoring.
Inhibition of vasoactive intestinal peptide (VIP), serotonin, gastrin, secretin, motilin, and pancreatic polypeptide secretion, reducing related clinical symptoms.
Decreased splanchnic blood flow and inhibition of gastrointestinal hormone-mediated vasodilation.
Suppression of luteinizing hormone (LH) response to gonadotropin-releasing hormone (GnRH), impacting reproductive hormone regulation.
Reduction in gallbladder contractility and bile secretion, predisposing to gallstones and biliary sludge.
Prolonged half-life compared to somatostatin, allowing sustained therapeutic effects.
Modulation of cardiac electrophysiology, including potential bradycardia and conduction abnormalities.
Inhibition of hormone secretion associated with neuroendocrine tumors, alleviating flushing, diarrhea, and other tumor-induced symptoms.

Therapeutic Or Clinical Uses

Treatment of acromegaly in patients with inadequate response to surgery, radiation, or bromocriptine.
Management of symptomatic metastatic carcinoid tumors presenting with severe flushing and diarrhea.
Control of profuse watery diarrhea associated with vasoactive intestinal peptide-secreting tumors (VIPomas).
Off-label use in other hormone-secreting neuroendocrine tumors requiring inhibition of peptide hormone release.
Reduction of gastrointestinal bleeding due to varices by decreasing splanchnic blood flow (off-label use).
Palliative management of hormone-related symptoms in various neuroendocrine neoplasms.
Diagnostic use in exploring somatostatin receptor expression in tumors via imaging techniques (with labeled analogs).
Adjunctive therapy to control hormone excess in complex endocrine disorders.
Potential investigational use in gastrointestinal motility disorders and pancreatic exocrine insufficiency.

Side Or Adverse Effects

Gallbladder abnormalities including gallstones, biliary sludge, biliary duct dilation, and cholelithiasis.
Sinus bradycardia occurring in approximately 25% of patients, with potential conduction abnormalities and arrhythmias.
Gastrointestinal disturbances such as diarrhea, loose stools, nausea, abdominal discomfort, flatulence, vomiting, constipation, and abdominal distension.
Hyperglycemia affecting up to 16% of acromegalic patients, and hypoglycemia in approximately 3%, necessitating glucose monitoring.
Hypothyroidism evidenced by decreased TSH and thyroid hormones requiring monitoring and possible thyroid hormone replacement.
Steatorrhea and malabsorption of dietary fats due to inhibition of pancreatic enzyme and bile acid secretion.
Injection site pain reported in around 7.7% of patients.
Headache, dizziness, fatigue, weakness, pruritus, joint pain, backache, and visual disturbances observed in smaller subsets.
Anaphylactoid reactions including rare cases of anaphylactic shock.
Pancreatitis and pancreatic exocrine insufficiency reported in some cases.
Hepatobiliary complications, including cholangitis, cholecystitis, and pancreatitis.
Hematologic effects such as thrombocytopenia.
Rare instances of intestinal obstruction with severe abdominal symptoms.
Injection site hematoma, bruising, and edema may also occur.
Flushing and depression noted as less common adverse effects.

Precautions

Careful cardiac monitoring for bradycardia, arrhythmias, and conduction blocks, especially in patients receiving intravenous octreotide.
Regular ultrasound assessment for gallbladder abnormalities; discontinue therapy if complications such as cholecystitis or biliary obstruction develop.
Monitor blood glucose levels closely; adjust antidiabetic medications to prevent hypo- or hyperglycemia.
Periodic thyroid function tests to detect and manage hypothyroidism.
Evaluate patients with new or worsening steatorrhea for pancreatic exocrine insufficiency; consider pancreatic enzyme supplementation if needed.
Vitamin B12 levels should be monitored during prolonged therapy due to potential deficiency.
Rotate injection sites to minimize local irritation and injection site reactions.
Use with caution in patients with severe renal or hepatic impairment; dose adjustments may be necessary.
Assess disease activity annually in irradiated acromegaly patients by temporarily withdrawing octreotide therapy.
Avoid concomitant continuous intravenous infusions at doses and durations beyond recommended limits due to safety concerns.
Not recommended for pediatric patients under 6 years due to lack of safety data and increased risk of serious adverse events.
Pregnant women should be counseled regarding potential risks; animal studies show no major teratogenicity but human data are limited.
Inform female patients of reproductive potential about potential for unintended pregnancy due to fertility improvement.
Avoid or adjust concomitant drugs that may prolong QT interval or cause bradycardia.
Do not mix octreotide with total parenteral nutrition solutions due to potential inactivation.

Warnings

Risk of complete atrioventricular (AV) block and other conduction abnormalities during intravenous administration, especially at high doses or continuous infusions.
High incidence of gallbladder disease including cholelithiasis, biliary sludge, and complications requiring discontinuation if suspected.
Potential for significant alterations in glucose metabolism leading to hypo- or hyperglycemia; careful monitoring is mandatory.
Development of hypothyroidism due to suppressed thyroid-stimulating hormone secretion necessitates regular thyroid function testing.
Steatorrhea and malabsorption related to inhibition of pancreatic enzymes and bile flow may cause nutritional deficiencies and weight loss.
Possible vitamin B12 deficiency with long-term therapy requiring monitoring and supplementation if indicated.
Reports of serious hypersensitivity reactions including anaphylaxis have been documented.
Use caution in patients with pre-existing cardiac disease, congestive heart failure, or those receiving medications that can cause bradycardia.
Limited safety data in pediatric patients; reports of serious adverse events including necrotizing enterocolitis and death in children under 2 years.
Increased risk of adverse effects in elderly patients due to altered pharmacokinetics.
Potential for worsening congestive heart failure has been reported; monitor clinical status carefully.
Discontinue drug if signs of pancreatitis or biliary tract infection develop.
Avoid use in patients with known hypersensitivity to octreotide or formulation components.
Careful dose titration recommended to minimize adverse effects while achieving therapeutic goals.
Interrupt therapy and evaluate if severe gastrointestinal symptoms resembling bowel obstruction occur.

Contraindication

Known hypersensitivity or allergy to octreotide acetate or any component of the formulation.
Patients with a history of severe hypersensitivity reactions to somatostatin analogs.
Use of octreotide in conditions where its pharmacodynamic effects may exacerbate underlying disease, unless benefits outweigh risks.
Intravenous use during surgical procedures requiring continuous infusion at doses exceeding approved recommendations, due to risk of cardiac conduction disturbances.

Drug Interactions

Cyclosporine: Octreotide may reduce absorption leading to decreased cyclosporine blood levels and potential transplant rejection; monitoring is essential.
Insulin and Oral Hypoglycemic Agents: Octreotide inhibits insulin and glucagon secretion; glucose monitoring and anti-diabetic dose adjustment required.
Bromocriptine: Concomitant use increases bromocriptine availability, necessitating careful dose titration.
Beta-blockers and other bradycardia-inducing drugs may have additive heart rate-lowering effects; monitor cardiac function closely.
CYP3A4 Substrates with Narrow Therapeutic Index (e.g., quinidine, terfenadine): Octreotide may decrease metabolic clearance by CYP450 suppression, use cautiously.
Lutetium Lu 177 Dotatate: Octreotide competes for somatostatin receptors and should be discontinued at least 24 hours prior to each lutetium dose to avoid interference.
Drugs affected by nutrient absorption may have altered pharmacokinetics, as octreotide reduces gastrointestinal motility and secretions.
No significant interactions with total parenteral nutrition as octreotide is incompatible and should not be mixed.
Potential minor interactions with thyroid hormone replacement therapies due to octreotide's suppression of TSH.
Close monitoring advised when coadministered with antihypertensives or agents affecting cardiac conduction.

Preparations Of The Drug

Octreotide Acetate Injection supplied as clear sterile solutions for subcutaneous or intravenous administration.
Single-dose vials available in strengths of 50 mcg/mL, 100 mcg/mL, and 500 mcg/mL, each containing 1 mL.
Multi-dose vials available as 5 mL vials with 200 mcg/mL (1,000 mcg/5 mL) and 1,000 mcg/mL (5,000 mcg/5 mL) strengths.
Formulations contain inactive ingredients: sodium chloride, sodium acetate trihydrate, glacial acetic acid, water for injection; multi-dose vials also contain phenol as preservative.
Molecular weight approximately 1,019.3 g/mol; amino acid sequence designed to mimic somatostatin with prolonged activity.
Packaging typically includes cartons of 10 single-dose vials or single multi-dose vials as per prescribed dosing.
Storage requires refrigeration at 2° to 8°C (36° to 46°F); stable for up to 14 days at room temperature protected from light.
Unused portions of single-dose vials must be discarded after opening; multi-dose vials should be discarded 14 days after first entry.
Ready-to-use solutions are isotonic and suitable for infusion or bolus administration following dilution in saline or dextrose solutions.
Container closure is free of natural rubber latex to minimize allergic risk.
Product supplied by Sagent Pharmaceuticals, manufactured in Canada, with specific National Drug Code (NDC) numbers for each vial strength.